Skip to main content

Phathom Pharmaceuticals, Inc.

PHAT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001783183

No open-market purchases or sales by Phathom Pharmaceuticals, Inc. insiders were filed in the last 90 days; 161 institutions reported holding it in 13F filings for Q2 2026, worth $782.1M in total; no superinvestor holds it.

Q1 2024 vs. Q4 2023

How the institutions holding Phathom Pharmaceuticals, Inc. changed between Q4 2023 and Q1 2024.

All holders in Q1 2024All holders in Q4 2023

13F holders of PHAT: Q4 2023 compared with Q1 2024
MeasureQ4 2023Q1 2024Change
Holders117114−3
Shares54.1M55.4M+1.29M (+2.4%)
Value$503.3M$588.2M+$84.9M (+16.9%)

New holders (13)

Institutions that held Phathom Pharmaceuticals, Inc. at the end of Q1 2024 but not at the end of Q4 2023.

Institutions new to PHAT in Q1 2024
InstitutionSharesValue% of portfolio
Jennison Associates LLC1,647,697$17.5M0.01%
Eagle Asset Management Inc304,839$3.23M0.02%
Prelude Capital Management, LLC22,044$234.1K0.02%
EntryPoint Capital, LLC19,380$205.8K0.18%
Gsa Capital Partners LLP14,174$151.0K0.01%
Klingman & Associates, LLC10,376$110.2K0.01%
Kestra Private Wealth Services, LLC10,000$106.2K0.00%
State Board of Administration of Florida Retirement System11,228$80.2K0.00%
FNY Investment Advisers, LLC5,000$53.0K0.03%
US Bancorp3,450$36.6K0.00%
Riggs Asset Managment Co. Inc.69$7330.00%
Nelson, Van Denburg & Campbell Wealth Management Group, LLC7$740.00%
CWM, LLC4$00.00%

Sold out (16)

Institutions that held Phathom Pharmaceuticals, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.